Susquehanna International Group
SABS icon

Susquehanna International Group’s SAB Biotherapeutics SABS Stock Holding History

Susquehanna International Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.6K Buy
+12,700
New +$50.6K ﹤0.01% 12641

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's SABS Position: Q1 2023 in Review

Susquehanna International Group sold out of SAB Biotherapeutics (SABS) in Q1 2023, closing a stake of 1,144 shares — an estimated $6.75K sold.

Susquehanna International Group first reported a position in SABS in Q4 2021 and held it in 2 quarters. The position peaked at $118K in Q4 2021. 39 funds tracked by Wall St. Rank hold SABS as of Q1 2023.

  • Susquehanna International Group reported no remaining SAB Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Susquehanna International Group sold 1,144 SAB Biotherapeutics shares in Q1 2023, an estimated $6.75K.
  • Susquehanna International Group first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 2 quarters.
  • Susquehanna International Group's SAB Biotherapeutics position peaked at $118K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.